Developing a new platform for testing drugs for Alzheimer's disease and traumatic brain injury
A physiologically relevant pre-clinical drug screening platform for Alzheimer's Disease and Traumatic Brain Injury with integrated stretchable microelectrodes
This study is working on a new tiny chip that mimics Alzheimer's disease and related conditions to help test new drugs, with the hope of finding better treatments for the millions of people affected by these diseases.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Bmseed, LLC NIH-funded |
| Lab location | 1 site (Tempe, United States) |
| Project ID | NIH-10997391 on NIH RePORTER |
What this research studies
This research focuses on creating an innovative microfluidic chip-based platform that models Alzheimer's disease and related dementias for preclinical drug testing. By integrating this platform with existing models for traumatic brain injury, the research aims to provide a more accurate representation of these conditions, which could lead to better drug development. Patients may benefit from this research as it seeks to address the lack of effective treatments for Alzheimer's disease, which currently affects millions. The approach involves advanced 3D cell culture techniques to simulate the disease environment more realistically.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals affected by Alzheimer's disease or related dementias, as well as those with a history of traumatic brain injury.
Not a fit: Patients with other forms of dementia unrelated to Alzheimer's or traumatic brain injury may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of effective treatments that stop or reverse the progression of Alzheimer's disease.
How similar studies have performed: Other research has shown promise with similar microfluidic platforms in modeling neurological diseases, indicating potential for success in this novel approach.
Where this research is happening
Tempe, United States
- Bmseed, LLC — Tempe, United States (Active)
Researchers
- Principal investigator: Graudejus, Oliver — Bmseed, LLC
- Study coordinator: Graudejus, Oliver
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.